Synthesis and quality control of the antibody-drug conjugate CMG901 was performed according to the internal protocol by Shanghai Miracogen Inc, and drug-to-antibody ratio (DAR) was set as approximately 3.8. Zolbetuximab analog was recombinantly expressed in CHO host cells according to the ...
CMG901 consists of a Claudin 18.2-specific antibody, a cleavable linker and a toxic load and methyl auristatin E (MMAE). [payload:microtubule (MT)抑制剂;海兔毒素衍生物]. DAR=4 研发机构 康诺亚 ;美雅珂 (乐普生物) ;AstraZeneca 最高研发阶段 全球: III期临床 中国: III期临床 审评审批类型...
ARX788是一种国产靶向HER2的ADC药物,在一项关于该药物的多中心、剂量递增的Ⅰ期临床实验中纳入30名晚期胃腺癌患者,其中27名患者(90%)既往接受了基于曲妥珠单抗治疗方案,12名患者(40%)接受了2线或2线以上治疗。接受ARX788治疗受试者中9名接受剂量为1.3 mg/kg,14名接受剂量为1.5 mg/kg,7名接受剂量为1.7 mg/kg...